Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210588 | 0.84 | HTT (0.45) | TDP1MAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL1267459 | 0.83 | MAPT (0.42) | TDP1MAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL11513312 | 0.81 | CA1 (0.39) | CA1CA2CA9TSHRTDP1 | |
| SCHEMBL3315142 | 0.80 | MAOB (0.36) | TDP1MAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL5251072 | 0.78 | KMT2A (0.52) | TDP1MAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL3805546 | 0.78 | HTT (0.45) | CA1CA2CA9TSHRTDP1 | |
| SCHEMBL6213159 | 0.76 | SOD1 (0.47) | TSHRTDP1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL2089078 | 0.75 | CA1 (0.45) | CA1CA2CA9TSHRTDP1 | |
| SCHEMBL1269005 | 0.74 | CYP3A4 (0.33) | MAPTPOLBALOX15HTTHSD17B10 | |
| SCHEMBL2641277 | 0.74 | TDP1 (0.56) | TSHRTDP1MAPTHTTS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0675895-B1 | ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER | PF MEDICAMENT (FR) | 1997-07-23 | — | — | EP | claimed |
| US-5643885-A | Etoposide derivatives, process for preparing them, their use as a medicinal product and their use for the preparation of a medicinal product intended for anti-cancer treatment | PIERRE FABRE MEDICAMENT (FR) | 1997-07-01 | — | — | US | claimed |
| JP-H08504795-A | — | — | 1996-05-21 | — | — | JP | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| CN-102532162-A | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2012-07-04 | — | — | CN | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0675895-B1 | ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER | PF MEDICAMENT (FR) | 1997-07-23 | — | — | EP | disclosed |
| US-5643885-A | Etoposide derivatives, process for preparing them, their use as a medicinal product and their use for the preparation of a medicinal product intended for anti-cancer treatment | PIERRE FABRE MEDICAMENT (FR) | 1997-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CA1 3493/4885CA2 1853/4885CA9 3134/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | CA1 2592/4885CA2 254/4885CA9 895/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | CA1 2592/4885CA2 254/4885CA9 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.